Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Kymes
Steven
S
D000577:Amides / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005901:Glaucoma / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008055:Lipids / Q000191:economics* / Q000627:therapeutic use; D009798:Ocular Hypertension / Q000188:drug therapy / Q000191:economics; D011461:Prostaglandins F, Synthetic / Q000191:economics / Q000627:therapeutic use; D000069557:Travoprost
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost